BFRIW Projected Dividend Yield

Wt Exp 10/27/2026/Biofrontera Inc ( NASDAQ : BFRIW )

Biofrontera is a biopharmaceutical company focusing on commercialization of pharmaceutical products. Co.'s principal product is Ameluz®, which is a prescription drug approved for use in combination with its licensor's medical device, which has been approved by the U.S. Food and Drug Administration, the BF-RhodoLED® lamp, for photodynamic therapy, or PDT, (when used together, Ameluz® PDT) in the U.S. for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. Co.'s second prescription drug product in its portfolio is Xepi® (ozenoxacin cream, 1%), a topical non-fluorinated quinolone that inhibits bacterial growth.

20 YEAR PERFORMANCE RESULTS